• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Alimera, Brill Pharma ink exclusive distribution deal for Iluvien intravitreal implant

March 13, 2017 By Sarah Faulkner

Alimera, Brill Pharma ink exclusive distribution deal for Iluvien intravitreal implantAlimera Sciences (NSDQ:ALIM) said today that it inked an exclusive distribution deal with Spain-based Brill Pharma for its Iluvien sustained-release intravitreal implant.

According to the agreement, Brill Pharma will promote, market and commercialize the diabetic macular edema implant in Spain. It will also negotiate with the Spanish Ministry of Health on the implant’s public price and the appropriate net price for reimbursement within the Spanish National Health System.

“As a continuous microdosing treatment that lasts for up to 3 years, Iluvien can make a major difference to patients with DME in Spain,” Alimera president & CEO Dan Myers said in prepared remarks. “With the help of Brill Pharma’s experienced team, we expect to reach Spanish patients and their physicians with a truly innovative product that can consistently treat their disease every day and markedly improve their quality of life.”

Healthcare practitioners use an applicator with a 25-gauge needle to inject the Iluvien intravitreal implant into the back of the patient’s eye. Each implant is designed to release microdoses of the corticosteroid flucinolone acetonide for 36 months.

“Spain has a strong tradition in the use of corticosteroids being one of the largest markets in Europe. The introduction of Iluvien will represent a substantial improvement in the long term management of the pathology and the quality of life of a significant number of patients. Brill Pharma will be the 1st pharmaceutical company with Spanish capital, marketing an innovative intravitreal product in diabetic macular edema,” Brill Pharma CEO Jordi Martinez Rotllan added.

ALIM shares were trading at $1.46 apiece in morning activity today, up 3.6%.

In February, Alimera and Knight Therapeutics (TSE:GUD) said that Health Canada accepted the companies’ New Drug Application for Iluvien.

pSivida (NSDQ:PSDV) licensed Iluvien to Alimera in 2008 and in July 2015, Knight and Alimera inked a deal granting Knight the exclusive distribution rights for Iluvien in Canada.

Filed Under: Featured, Implants, Optical/Ophthalmic, Wall Street Beat Tagged With: Alimera Sciences, Brill Pharma, Knight Therapeutics

IN CASE YOU MISSED IT

  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS